{'_data': [['Unknown',
            [['GI',
              u'4.0%), abdo min al pain (3.5% vs. 3.3%), diarrhoe a (3.0% vs. 2.7%). Uncom mo n: gastritis (0.9% vs. 0.7%), oesoph a gitis (0.9% vs. 0.9%), dysph a gi a (0.4% vs. 0.2%), duode nitis (0.2% vs. 0.1%), oesoph a g e a l ulcer (0.2% vs. 0.2%) Rare: glossitis (<0.1% vs. 0.1%), oesoph a g e a l stricture (<0.1% vs. 0.0%). Musculoskeletal and connective tissues disorders: Commo n: musc ulosk el e t al pain (2.1% vs. 1.9%). Investigations: Rare: abnor m al liver function tests.* Laboratory findings: Early, transie nt, asymp t o m a ti c and mild decre a s e s in seru m calcium and phosph a t e levels have been observe d in some patient s. The following additional adver s e reactions have been report e d during post- marke ting use (frequ e nc y unknown): Eye disorders: Iritis, uveitis. Muskuloskeletal and connective tissues disorders: Osteon e c ro sis of the jaw. Skin and subcutaneous tissue disorders: Hypers e n sitivity and skin reactions, including angioe d e m a , gener alise d rash, and bullous skin reactions, some sever e. * No releva nt incidenc e s from Phase III osteopor osis studies; freque nc y base d on adver s e event/labor a t or y/r e c h allen g e findings in earlier clinical trials.']]]],
 '_pages': [4, 5],
 u'_rank': 1,
 u'_type': u'LSFU'}